AGTR1 Analysis Service

Are you currently facing challenges such as inconsistent data in GPCR signaling studies, difficulty in quantifying low-abundance membrane receptors, or complex validation requirements for hypertensive drug targets? Our AGTR1 Analysis Services provide refined high-resolution mapping and physiological assessment of Angiotensin II Receptor Type 1 via our exclusive ultra-precise single-target biomarker testing system and premium engineered molecular instruments. Drive your investigations from early verification to longitudinal patient observation with the specialized technical support from Creative Biolabs.

Contact our team to get an inquiry now!

Introduction of AGTR1: The Critical Gateway of the Renin-Angiotensin System

The Angiotensin II Receptor Type 1 (AGTR1) is a pivotal G protein-coupled receptor (GPCR) that mediates the majority of the biological effects of Angiotensin II, the primary effector molecule of the Renin-Angiotensin System (RAS). Located on chromosome 3q24, the AGTR1 gene encodes a protein that is essential for maintaining blood pressure homeostasis and fluid-electrolyte balance. Structurally, AGTR1 consists of seven transmembrane alpha-helices, which undergo conformational changes upon ligand binding to activate downstream signaling cascades.

Scientific literature consistently identifies AGTR1 as a central player in both physiological and pathological processes. Activation of AGTR1 triggers the G_q/11 pathway, stimulating phospholipase C (PLC) and leading to an increase in intracellular calcium and activation of protein kinase C (PKC). Furthermore, it interacts with the JAK/STAT and MAPK/ERK pathways, promoting cell growth and inflammatory responses. Dysregulation or overactivation of AGTR1 is intrinsically linked to major global health burdens, including essential hypertension, diabetic nephropathy, cardiac hypertrophy, and atherosclerosis. Recent studies also highlight the role of AGTR1 autoantibodies in preeclampsia and transplant rejection, positioning this receptor not just as a drug target, but as a critical diagnostic biomarker.

Fig.1 Major AGTR1 signalling pathways linked to cancer cell proliferation, angiogenesis and EMT.¹

Application of AGTR1 Analysis

Our analysis services are designed to support a broad spectrum of research and diagnostic development needs:

• Drug Screening and Lead Optimization: Evaluate the efficacy of Angiotensin II Receptor Blockers (ARBs) and novel small molecule antagonists.
• Biomarker Discovery: Quantify AGTR1 levels in patient samples to identify correlations with cardiovascular risk factors or chronic kidney disease (CKD) progression.
• Transplantation Research: Detect and quantify anti-AGTR1 antibodies which are critical markers for non-HLA mediated graft rejection.
• Metabolic Syndrome Studies: Analyze the role of AGTR1 in insulin resistance and adipose tissue inflammation.
• Pathological Profiling: Utilize high-resolution imaging and quantitative assays to study receptor up-regulation in hypertrophic heart tissue.

Service Highlights

Choosing Creative Biolabs for your AGTR1 analysis ensures access to industry-leading precision and reliability. Our services are distinguished by:

Service Workflow

FAQs

1. What is the limit of detection for AGTR1 in micro-volume clinical samples?

   High-sensitivity immunoassay platforms utilizing advanced signal amplification can accurately quantify AGTR1 levels in volumes as low as 25–50 μL. This allows for robust data generation from limited matrices like pediatric serum or cerebrospinal fluid.

2. How is the molecular specificity of AGTR1 maintained against closely related GPCRs like AGTR2?

   Specificity is primarily achieved through the selection of antibodies targeting unique extracellular loops or C-terminal domains that exhibit low sequence homology between AGTR1 and AGTR2. Validation techniques, including competitive ELISA with recombinant AGTR2 decoys and Western blotting in receptor-knockout cell lines, confirm the absence of cross-reactivity.

3. What factors influence the detection of AGTR1 in FFPE tissue sections?

   Fixation-induced cross-linking can mask AGTR1 epitopes, particularly within its seven-transmembrane domains. Effective detection requires optimized heat-induced epitope retrieval (HIER) using high-pH buffers to break methylene bridges, followed by the use of IHC-validated antibodies that recognize linear or semi-conformational epitopes.

4. What documentation is scientifically necessary for validating AGTR1 as a diagnostic biomarker?

   Comprehensive validation requires analytical performance data including linearity, precision (intra- and inter-assay CV), sensitivity (LOD/LOQ), and interference testing. These data points, along with detailed SOPs and raw chromatographic or spectrophotometric results, form the technical basis for subsequent clinical validation and regulatory submission.

5. What determines the analytical timeline for a high-throughput AGTR1 screening project?

   The duration is influenced by the complexity of the sample matrix and the required optimization of reagent concentrations. Typically, a validated workflow, from sample preparation and QC through to statistical interpretation, requires 3 to 5 weeks to ensure data reproducibility and scientific rigor.

Creative Biolabs is your premier partner for AGTR1 Analysis Services, offering an unparalleled blend of technical precision, customized workflows, and expert scientific support. Whether you are in the early stages of drug discovery or conducting late-stage clinical biomarker validation, our one-stop solution ensures that your project moves forward with confidence and clarity.

Reference

1. Singh, Anukriti et al. "Role and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastases." European journal of pharmacology vol. 763,Pt B (2015): 178-83. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.ejphar.2015.05.011

For Research Use Only.